Akero Looks Ahead To Phase III In Cirrhotic NASH Despite Phase IIb Miss On Fibrosis

 
• By Joseph Haas
Mixed data
Investors and analysts differed on the meaning of Akero's latest NASH data • Source: Shutterstock

More from Clinical Trials

More from R&D